6 Growing Areas

2More Testing of “Difficult Diseases”

Drug development companies have been able to address a phenomenal number of health issues; however, one could consider these diseases to be easier-to-treat or better understood, as to the factors that cause the disease. Now, the industry is turning their efforts and focus towards more difficult conditions, such as cancer, neurological diseases, emerging infectious diseases and rare or orphan diseases. This requires substantially more investment